[ad_1]
Check-in 2020.05.14 14:24
The | Revision 2020.05.14 15:35
Pasteur Korea, experiment with lung cells
“It is expected to help improve the symptoms of pneumonia”
“The ‘Napamostat’ showed the highest antiviral efficacy against the coronavirus among the approximately 3,000 drugs analyzed by the laboratory through cell culture experiments,” said Pasteur Korea. Compared to, it is hundreds of times higher. “It is the result of a study on ‘new drug recreation’ that finds drugs that are already approved or in the development stage and that can be applied to the treatment of patients with a crown.
Napamo Start is a drug manufactured by the Japanese pharmaceutical company Torii, and is sold by national pharmaceutical companies like Cheil Pharmaceuticals under a generic (drug) license.
The results of the study were published on the 12th (local time) on the site prior to the post of the document “Bio Archive (bioRxiv)”. However, the document has not been published through a formal review process such as peer review.
The researchers experimented with human lung cells instead of monkey kidney cells, which are commonly used in coronavirus studies. By comparing the drugs, the researchers found that Napamostat had the best effect. “It is expected to help improve symptoms of acute pneumonia caused by the corona infection,” the researchers said.
Currently, national and foreign clinical studies related to ‘napamostart’ are being carried out. Napamostat was immediately approved for clinical trials because it has already been approved for safety. To quickly confirm efficacy, the Pasteur Institute of Korea conducted a cell experiment. In Korea, according to the results of this study by the Korean Pasteur Institute, clinical trials have been conducted with 10 hospitals with the approval of the Ministry of Food and Drug Safety. In addition, clinical trials are underway abroad in Italy and Japan.
Ryu Wang-sik, head of the Korean Pasteur Research Institute, said: “Napamostat, which has a cellular antiviral effect several hundred times greater than Remdesivir, which has recently been approved for emergency use in the United States, is expected to United, help finish the crown. ” Napamostat is a medication that was originally used as an anticoagulant, so it is expected to help greatly improve the symptoms of pneumonia, such as thrombus, one of the main pathologies of crown pneumonia. “
